Wang Xin, Zhang Yuhan, Shi Leilei, Zhu Hongzhe, Shangguan Huizi, Ding Ling, Zhang Dongdong, Deng Chong, Liu Jiping, Xie Yundong
Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1 Middle Section of Century Avenue, Xianyang, 712046, People's Republic of China.
Department of Pharmacology, Shaanxi University of Chinese Medicine, No. 1 Middle Section of Century Avenue, Xianyang, 712046, People's Republic of China; Key Laboratory of Pharmacodynamic Mechanism and Material Basis of Traditional Chinese Medicine, Shaanxi Administration of Traditional Chinese Medicine, Xianyang, 712046, People's Republic of China; Shaanxi Key Laboratory for Safety Monitoring of Food and Drug, Xianyang, 712046, People's Republic of China.
J Ethnopharmacol. 2025 Feb 11;341:119319. doi: 10.1016/j.jep.2025.119319. Epub 2025 Jan 6.
Dioscorea bulbifera L. (DBL) was a traditional Chinese medicine commonly used to treat goitre and cancer. Nevertheless, its clinical application may lead to liver injury. Glycyrrhiza uralensis Fisch. (GRR) was primarily utilized in traditional Chinese medicine for its ability to harmonize various medicines and mitigate the toxic effects of poisonous herbs. However, the role of GRR in mitigating the liver toxicity of DBL has not been established after combination.
This study aimed to clarify the protective effect of GRR against DBL-induced liver injury in mice and investigate its mechanisms of action.
75% ethanol was employed to extract DBL and GRR. The extracted components were characterized using LC-MS. Mice were orally gavaged with extracts from each group for 30 days. After the experiment, the pathological changes in the liver of mice were evaluated. Additionally, biochemical markers associated with liver injury were assessed. The primary mechanisms through which GRR mitigates DBL-induced liver injury and the modulation of the liver-intestinal axis by GRR were explored utilizing untargeted metabolomics, targeted BAs metabolomics and 16S rDNA analyses. Furthermore, Western blot and qPCR assessed the protein and mRNA transcription of the farnesoid X receptor (FXR) and nuclear factor-erythroid 2-related factor 2 (Nrf2) as well as BA-related transporters.
GRR dose-dependently attenuated DBL-induced liver injury in mice. It mitigated hepatic pathological changes and alleviated hepatic inflammation and oxidative stress. GRR improved metabolic disorders induced by DBL in mice at the metabolite level, focusing on the ABC transporter. Moreover, GRR may be attributed to its activation of FXR/Nrf2 expression, reduction of cholesterol 7-alpha hydroxylase (CYP7A1) expression, promotion of bile salt export pump (BSEP), multi-drug resistance protein 2 (MRP2), P-glycoprotein (P-gp) and sodium taurocholate cotransport polypeptide (NTCP) expression, reduction of bile acid (BA) synthesis, promotion of BA efflux and reabsorption, and improvement of BA metabolic disorders. In addition, GRR ameliorated DBL-induced intestinal barrier injury and improved the structural organization of the intestinal flora, restoring the overall composition of the intestinal microbiota.
GRR exhibited significant alleviation of DBL-induced liver injury, potentially by modulating FXR/Nrf2-BA-related proteins, reducing hepatic BA accumulation, mitigating liver inflammation and oxidative stress, and regulating intestinal flora.
黄独(DBL)是一种传统中药,常用于治疗甲状腺肿和癌症。然而,其临床应用可能导致肝损伤。甘草(GRR)在传统中药中主要因其能调和诸药及减轻有毒草药的毒性作用而被使用。然而,GRR在与DBL联合使用后减轻其肝毒性的作用尚未明确。
本研究旨在阐明GRR对DBL诱导的小鼠肝损伤的保护作用,并探讨其作用机制。
采用75%乙醇提取DBL和GRR。提取的成分用液相色谱-质谱联用仪(LC-MS)进行表征。小鼠口服各实验组提取物30天。实验结束后,评估小鼠肝脏的病理变化。此外,评估与肝损伤相关的生化标志物。利用非靶向代谢组学、靶向胆汁酸代谢组学和16S核糖体DNA(rDNA)分析,探究GRR减轻DBL诱导的肝损伤的主要机制以及GRR对肝肠轴的调节作用。此外,蛋白质免疫印迹法(Western blot)和定量聚合酶链反应(qPCR)评估法尼酯X受体(FXR)、核因子红细胞2相关因子2(Nrf2)以及与胆汁酸相关的转运蛋白的蛋白质和信使核糖核酸(mRNA)转录水平。
GRR剂量依赖性地减轻DBL诱导的小鼠肝损伤。它减轻了肝脏病理变化,缓解了肝脏炎症和氧化应激。GRR在代谢物水平改善了DBL诱导的小鼠代谢紊乱,主要集中在ABC转运蛋白方面。此外,GRR可能归因于其激活FXR/Nrf2表达、降低胆固醇7α羟化酶(CYP7A1)表达、促进胆盐输出泵(BSEP)、多药耐药蛋白2(MRP2)、P-糖蛋白(P-gp)和牛磺胆酸钠共转运多肽(NTCP)表达、减少胆汁酸(BA)合成、促进BA外排和重吸收以及改善BA代谢紊乱。此外,GRR改善了DBL诱导的肠道屏障损伤,改善了肠道菌群的结构组织,恢复了肠道微生物群的整体组成。
GRR对DBL诱导的肝损伤具有显著的缓解作用,可能是通过调节FXR/Nrf2-胆汁酸相关蛋白、减少肝脏胆汁酸蓄积、减轻肝脏炎症和氧化应激以及调节肠道菌群来实现的。